Clinical Trial Update: A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression [Phase 3]

View source ↗

Summary

Phase 3 trial to compare Azenosertib (ZN-c3) against investigator's choice chemotherapy in platinum-resistant high-grade serous ovarian, primary peritoneal, or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Ovarian Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Azenosertib (azenosertib)

Snippet

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Conditions: Ovarian Cancer | Phase 3 | Status: NOT_YET_RECRUITING